Active Pharma Ingredient Market: Rising Growth, Ongoing Trends, Demands, Current As Well As The Future Challenges, Regional Analysis And In-depth Analysis Of Industry Players

Active Pharmaceutical Ingredient (API) produces the intended effects in a drug. A drug can contain a single API or have multiple API for the treatment of different symptoms in a particular disease. According to the U.S. Food and Drug Administration, any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product.

The increasing prevalence of chronic diseases is expected to boost the growth of the global active pharmaceutical ingredients market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018. Moreover, high incidence of cardiovascular diseases (CVDs) is also expected to aid in the growth of the market. For instance, according to the American Heart Association’s Heart Disease and Stroke Statistics 2018, around 92.1 million adults in the U.S. are suffering from some form of CVD or the after-effects of stroke.

Get Sample Research Report- https://www.stratagemmarketinsights.com/sample/9922

R&D in API is expected to offer lucrative growth opportunities for players in the global active pharmaceutical ingredients market. For instance, in June 2019, researchers from Bristol-Myers Squibb reported advantages of utilizing population balance modeling of crystallization processes for particle size distribution prediction of an API, in the journal MDPI Processes. Moreover, the development of ionic liquid APIs is also expected to aid in the growth of the market. For instance, in November 2018, researchers from the University of Vigo, Spain, reported the transformation of two solid APIs, indomethacin and mebendazole, into new API- ionic liquids.

However, stringent regulations, higher manufacturing costs, and increased competition are some of the factors that are expected to hinder the growth of the global active pharmaceutical ingredients market. For instance, in November 2019, Teva Pharmaceuticals halted production at its API plant in Italy, owing to a mandate of regulatory authorities to submit new registration requests for products produced at the site.

Major players in the market are focused on investment in R&D of APIs to expand their product portfolio. For instance, in April 2018, STA Pharmaceutical, a subsidiary of WuXi AppTec, signed an investment agreement with the government of Shanghai to build a new R&D center for APIs and intermediates.

Key Takeaways:

Increasing prevalence of chronic diseases to augment the growth of the global active pharmaceutical ingredients market over the forecast period

R&D in API is expected to offer lucrative growth opportunities for players in the market

Major players operating in the global active pharmaceutical ingredients market include Albemarle, Aurobindo Pharma, BASF, Bayer, Biocon, Boehringer Ingelheim GmbH, Cambrex, Cipla, Dr. Reddy's Laboratories, DSM, Haerbin Pharmaceutical Group, Hisun Pharmacy, Huahai Pharmaceutical, Jiangsu Hengrui Medicine, Johnson & Johnson, Johnson Matthey, Lonza Group, Lupin, Mylan, North China Pharmaceutical Group, North East Pharmaceutical, Novartis, Pfizer, Roche, Shandong Lukang Pharmaceutical, Shandong Xinhua Pharmaceutical, STA Pharmaceutical, Sun Pharmaceutical Industries, Teva Pharmaceuticals, Tian Yao, and Zhejiang Medicine

This report focuses on top manufacturers in the global market, with production, price, revenue, and market share for each manufacturer, covering
⤍ Teva
⤍ Novartis
⤍ Pfizer
⤍ Johnson & Johnson
⤍ Mylan
⤍ North China Pharmaceutical Group
⤍ Dr. Reddy's Laboratories
⤍ Roche
⤍ Aurobindo pharma
⤍ Sun Pharmaceutical Industries
⤍ Boehringer Ingelheim GmbH
⤍ Bayer
⤍ BASF
⤍ DSM
⤍ Zhejiang Medicine
⤍ Biocon
⤍ Johnson Matthey
⤍ Hisun Pharmacy
⤍ Cambrex
⤍ Shandong Xinhua Pharmaceutical
⤍ Lonza group
⤍ Huahai Pharmaceutical
⤍ Haerbin Pharmaceutical Group
⤍ Cipla
⤍ Tian Yao
⤍ Lupin
⤍ North East Pharmaceutical
⤍ Albemarle
⤍ Shandong Lukang Pharmaceutical
⤍ Jiangsu Hengrui Medicine

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into
⤍ Innovative Active Pharmaceutical Ingredients
⤍ Generic Active Pharmaceutical Ingredients

By Application, the market can be split into
⤍ Oncology
⤍ Cardiovascular Disease
⤍ Diabetes
⤍ Central Nervous System and Neurological Disorders
⤍ Endocrinology
⤍ Other Therapeutic Applications

By Regions, this report covers (we can add the regions/countries as you want)
⤍ North America
⤍ China
⤍ Europe
⤍ Southeast Asia
⤍ Japan
⤍ India

Buy Now- https://www.stratagemmarketinsights.com/cart/9922

[**NOTE: If you have any special requirements, please let us know and we will offer you the report as you want.]

Contact Us:
Mr. Shah
Stratagem Market Insights
Tel: US +1 415 871 0703 / JAPAN +81-50-5539-1737
Email: sales@stratagemmarketinsights.com
Explore By- SK

About Stratagem Market Insights:

Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with an cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide. Our reports cover various end-use industries such as Aerospace and Defense, Agriculture, Food and Beverages, Automotive, Chemicals and Materials, Consumer Goods and Retail, Electronics, Energy, Mining, and Utilities, Pharmaceuticals, Manufacturing and Construction, Services, and Healthcare, and ICT.

This release was published on openPR.